Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence
- PMID:17145880
- DOI: 10.1158/0008-5472.CAN-06-1570
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence
Abstract
Prostate cancer biology varies from locally confined tumors with low risk for relapse to tumors with high risk for progression even after radical prostatectomy. Currently, there are no reliable biomarkers to predict tumor relapse and poor clinical outcome. In this study, we correlated expression patterns of the androgen receptor (AR) coactivators lysine-specific histone demethylase 1 (LSD1) and four and a half LIM-domain protein 2 (FHL2), AR, Gleason score, Gleason grade, and p53 expression in clinically organ confined prostate cancers with relapse after radical prostatectomy. Our data reveal that high levels of LSD1, nuclear expression of the FHL2 coactivator, high Gleason score and grade, and very strong staining of nuclear p53 correlate significantly with relapse during follow-up. No correlation exists with relapse and the expression of AR and cytoplasmic expression of FHL2. To confirm these data, we did quantitative reverse transcription-PCR and Western blot analyses in a subset of tumor specimens. Consistently, both LSD1 mRNA and protein levels were significantly up-regulated in high-risk tumors. We previously identified LSD1 and FHL2 as nuclear cofactors interacting specifically with the AR in prostate cells and showed that both stimulate androgen-dependent gene transcription. Our present study suggests that LSD1 and nuclear FHL2 may serve as novel biomarkers predictive for prostate cancer with aggressive biology and point to a role of LSD1 and FHL2 in constitutive activation of AR-mediated growth signals.
Similar articles
- Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.Heemers HV, Regan KM, Dehm SM, Tindall DJ.Heemers HV, et al.Cancer Res. 2007 Nov 1;67(21):10592-9. doi: 10.1158/0008-5472.CAN-07-1917.Cancer Res. 2007.PMID:17975004
- Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression.Wissmann M, Yin N, Müller JM, Greschik H, Fodor BD, Jenuwein T, Vogler C, Schneider R, Günther T, Buettner R, Metzger E, Schüle R.Wissmann M, et al.Nat Cell Biol. 2007 Mar;9(3):347-53. doi: 10.1038/ncb1546. Epub 2007 Feb 4.Nat Cell Biol. 2007.PMID:17277772
- Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate.Kinoshita M, Nakagawa T, Shimizu A, Katsuoka Y.Kinoshita M, et al.Int J Urol. 2005 Apr;12(4):390-7. doi: 10.1111/j.1442-2042.2005.01093.x.Int J Urol. 2005.PMID:15948728
- Expression and function of androgen receptor coactivators in prostate cancer.Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A.Culig Z, et al.J Steroid Biochem Mol Biol. 2004 Nov;92(4):265-71. doi: 10.1016/j.jsbmb.2004.10.003. Epub 2004 Dec 19.J Steroid Biochem Mol Biol. 2004.PMID:15663989Review.
- New roles of flavoproteins in molecular cell biology: histone demethylase LSD1 and chromatin.Forneris F, Battaglioli E, Mattevi A, Binda C.Forneris F, et al.FEBS J. 2009 Aug;276(16):4304-12. doi: 10.1111/j.1742-4658.2009.07142.x. Epub 2009 Jul 14.FEBS J. 2009.PMID:19624733Review.
Cited by
- Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.Gupta S, Weston A, Bearrs J, Thode T, Neiss A, Soldi R, Sharma S.Gupta S, et al.Prostate Cancer Prostatic Dis. 2016 Dec;19(4):349-357. doi: 10.1038/pcan.2016.21. Epub 2016 Jun 28.Prostate Cancer Prostatic Dis. 2016.PMID:27349498Free PMC article.
- Roles of histone methyl-modifying enzymes in development and progression of cancer.Suzuki T, Terashima M, Tange S, Ishimura A.Suzuki T, et al.Cancer Sci. 2013 Jul;104(7):795-800. doi: 10.1111/cas.12169. Epub 2013 May 9.Cancer Sci. 2013.PMID:23560485Free PMC article.Review.
- Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast.Serce N, Gnatzy A, Steiner S, Lorenzen H, Kirfel J, Buettner R.Serce N, et al.BMC Clin Pathol. 2012 Aug 24;12:13. doi: 10.1186/1472-6890-12-13.BMC Clin Pathol. 2012.PMID:22920283Free PMC article.
- Pharmacological Inhibition of LSD1 for Cancer Treatment.Yang GJ, Lei PM, Wong SY, Ma DL, Leung CH.Yang GJ, et al.Molecules. 2018 Dec 4;23(12):3194. doi: 10.3390/molecules23123194.Molecules. 2018.PMID:30518104Free PMC article.Review.
- Deregulation of the Histone Lysine-Specific Demethylase 1 Is Involved in Human Hepatocellular Carcinoma.Kim S, Bolatkan A, Kaneko S, Ikawa N, Asada K, Komatsu M, Hayami S, Ojima H, Abe N, Yamaue H, Hamamoto R.Kim S, et al.Biomolecules. 2019 Dec 1;9(12):810. doi: 10.3390/biom9120810.Biomolecules. 2019.PMID:31805626Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous